These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33026750)

  • 1. Cutaneous Manifestations of EGFR-Inhibitors in African Americans and Treatment Considerations.
    Geisler AN; Noor SJ
    J Drugs Dermatol; 2020 Sep; 19(9):894-896. PubMed ID: 33026750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
    Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
    Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.
    Lacouture ME; Wainberg ZA; Patel AB; Anadkat MJ; Stemmer SM; Shacham-Shmueli E; Medina E; Zelinger G; Shelach N; Ribas A
    Cancer Discov; 2021 Sep; 11(9):2158-2167. PubMed ID: 33910927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and grading of EGFR inhibitor-induced cutaneous toxicity.
    Beech J; Germetaki T; Judge M; Paton N; Collins J; Garbutt A; Braun M; Fenwick J; Saunders MP
    Future Oncol; 2018 Oct; 14(24):2531-2541. PubMed ID: 29727211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
    Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
    Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
    Front Immunol; 2021; 12():737311. PubMed ID: 34557197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
    Gorji M; Joseph J; Pavlakis N; Smith SD
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach.
    Gobbo M; Ottaviani G; Mustacchi G; Di Lenarda R; Biasotto M
    Lasers Med Sci; 2012 Sep; 27(5):1085-90. PubMed ID: 22120470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
    Rothschild SI; Betticher D; Zenhäusern R; Anchisi S; von Moos R; Pless M; Moosmann P; Popescu RA; Calderoni A; Dressler M; Rauch D; Pederiva S; Woelky R; Papet C; Bühler V; Borner M
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):881-889. PubMed ID: 31444619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.
    Baas J; Krens L; Bohringer S; Mol L; Punt C; Guchelaar HJ; Gelderblom H
    PLoS One; 2018; 13(12):e0208080. PubMed ID: 30557370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibitor-induced cut-like skin lesions of the fingers.
    Iskandar AS; Hwang A; Dasanu CA
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30068575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.
    Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK
    Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
    Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
    Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.
    Jarząbek T; Rucińska M; Rogowski W; Lewandowska M; Tujakowski J; Habib M; Kowalczyk A; Byszek A; Dziadziuszko R; Nawrocki S
    Mol Diagn Ther; 2015 Apr; 19(2):79-89. PubMed ID: 25721848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
    Tohyama M; Hamada M; Harada D; Kozuki T; Nogami N; Monden N; Kajiwara T; Nishina T
    J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.